New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
July 9, 2020 - Osmotica Pharmaceuticals announced the FDA approval of Upneeq (oxymetazoline), for the treatment of acquired blepharoptosis in adults.
Download PDF
Return to publications
